Business
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
LUPKYNIS® achieved significantly earlier reductions in UPCR and significantly higher renal response rates in lupus nephritis patients with high proteinuria,
About this update from Aurinia Pharmaceuticals Inc
[{"type":"text","content":"\n\nLUPKYNIS® achieved significantly earlier reductions in UPCR and significantly higher renal response rates in lupus nephritis patients with high proteinuria, compared to patients treated with mycophenolate mofetil and low-dose steroids alone, in a pooled, post-hoc analysis.1\n\n\n\nLUPKYNIS® was associated with a higher rate of renal secretion and lower overall exposure to kidney tissue, which may be associated with an improved safety profile, compared to cyclosporine and tacrolimus, in an animal study.2\n\n\n\nLUPKYNIS® did not inhibit the kidney tubular reabsorption of calcium and magnesium and therefore does not cause hypercalciuria or hypomagnesemia, in contrast to tacrolimus, in an animal study.3\n\n\n\n EDMONTON, Alberta--(BUSINESS WIRE)--\nAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced three oral presentations at the Annual Meeting of the European Renal Association (ERA), providing additional support for the efficacy and safety of LUPKYNIS® (voclosporin), a next generation calcineurin inhibitor (CNI) approved in the U.S. and Europe for the treatment of adults with active lupus nephritis (LN).\n\n\nOne oral presentation included results of a post-hoc, pooled analysis of the Phase 2 AURA-LV (NCT02141672) and Phase 3 AURORA 1 (NCT03021499) studies showing that LUPKYNIS® taken with mycophenolate mofetil (MMF) and low-dose steroids resulted in significantly higher renal response rates and significantly earlier reductions in UPCR in LN patients with high proteinuria (≥2 mg/mg), compared to MMF and low-dose steroids alone.1 These findings are meaningful, as recent post-hoc analyses with monoclonal antibody therapies demonstrated limited efficacy in patients with LN and moderate to high proteinuria (UPCR ≥2 to ≥3 mg/mg), potentially due to an increase in renal antibody clearance.4-7\n\n\n“Lupus nephritis is a common and serious manifestation of lupus and can lead to significant kidney damage without appropriate treatment. The findings presented at ERA this week show that voclosporin achieved a 50% proteinuria reduction at 28 days, compared to 57 days in the control arm (p90% renal reabsorption was observed for both CSA and TAC in this study, whereas the renal handling of VCS suggested a significant component of tubular secretion. The higher rate of secretion and lower overall exposure of k...